Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Kenji Tamura et al.|The Lancet Oncology|2021Cited by 412
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAntonio González-Martı́n, Jonathan A. Ledermann, Philipp Harter et al.|Annals of Oncology|2023Cited by 381
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJonathan A. Ledermann, Anna Fagotti, Xavier Matías‐Guiu et al.|Annals of Oncology|2024Cited by 277
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Wolfgang P. Fendler, Rainer Hamacher et al.|Journal of Nuclear Medicine|2022Cited by 68
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter StudyLucas Minig, Christina Fotopoulou, Florian Heitz et al.|Annals of Surgical Oncology|2017Cited by 54